The research of the group is rooted in a long standing expertise on protein structure, stability and folding, and protein-ligand interactions, using a wide range of experimental and computational approaches. The main research focus has been directed to the study of molecular mechanisms of amyloid diseases, in particular transthyetin-dependent amyloidosis (ATTR), and the discovery and development of small-molecule therapeutics, an effort that lead to the creation of a spin-off biotech company (BSIM Therapeutics). More recently, the group has also expanded its interests in the identification and validation of biological targets in the areas of neuroinflammation and anti-virals.